Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions

Learn 7 molecular methods that empower
immuno-oncology trials

Download nowLearn about seven key molecular methods in our complimentary insight brief  that provide insights for better informed decisions and clinical development outcomes for immuno-oncology trials.

Immuno-oncology (IO) drug development requires an enhanced understanding of the complex interactions of the immune system and cancer. Genomic based solutionsGenomics can uncover new insights into these complex interactions through the molecular characterization of host and tumor cells.

With the ability to address challenges in biomarker analysis, our genomic solutions combined with our industry-leading bioinformatics team demonstrate our commitment to design smarter trials for our customers by:
  • Identifying biomarkers
  • Discovering new pathways
  • Selecting the right patients
  • Developing safer, more effective medicines
Contact us to discover how we can develop comprehensive genomic strategies to help you achieve better outcomes for your IO program.


Learn about the authors:
Wendell Jones, Ph.D., Principal Bioinformaticist and Scientific Advisor, Q2 Solutions | EA Genomics
Patrick Hurban, Ph.D., Senior Director and Global Head, Translational Genomics, Q2 Solutions | EA Genomics
Best Practices for Integrating Biomarkers across the Drug Development Continuum

A roadmap for a successful biomarker strategy

Gene expression for keeping pace with immuno-oncology breakthroughs and biomarker identification

When and how to use gene expression profiling

Companion Diagnostic Development: Current trends and recommendations

The Power of the Central Laboratory for Immuno-Oncology Drug Development

Companion Diagnostics

Extension expertise to accelerate your tandem development pathway

Read More